David Adler, MD
Interventional Cardiology · Virginia Beach, VANPI 1588711386
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,065 of the $14,849 with a category attached, or 61.0%. 27 manufacturers reported payments, led by Abbott at 33.0% of the total. Reporting peaked in 2019 at $6,110 and has fallen 92.7% since, to $445 in 2025.
Across 192 payments — averaging $77.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Edwards Lifesciences$3K
- Boston Scientific$3K
- Medtronic$1K
- Abiomed$904
- Corindus Inc.$508
- plus $1K from 21 others
Across 17 payments — averaging $2577.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Penumbra, Inc.$33K
- Edwards Lifesciences$10K
What the payments were for
- Travel & lodging$5,78439%
- Food & beverage$9,06561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 49 | $4,903 |
| Edwards Lifesciences | 23 | $3,122 |
| Boston Scientific | 26 | $2,709 |
| Medtronic(2 entities) | 31 | $1,387 |
| Abiomed | 11 | $904 |
| Corindus Inc. | 4 | $508 |
| Biotronik Inc. | 2 | $235 |
| Philips North America LLC | 3 | $212 |
| Boehringer Ingelheim | 2 | $136 |
| ZOLL Circulation Inc | 1 | $113 |
| Regeneron Healthcare Solutions, Inc. | 7 | $111 |
| Johnson & Johnson | 8 | $88 |
| Cardiovascular Systems Inc. | 2 | $66 |
| Janssen Scientific Affairs, LLC | 2 | $60 |
| Novartis | 3 | $42 |
| Astellas Pharma US Inc | 3 | $41 |
| Pfizer | 3 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| AstraZeneca | 2 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Nuwellis, Inc. | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $15 |
| Smith+Nephew | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| Aegerion Pharmaceuticals, Inc. | 1 | $13 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,916
- Mitra Clip system$1,646
- Watchman$1,567
- MitraClip$760
- Impella$539
- COREVALVE EVOLUT R$517
- CorPath GRX$403
- WATCHMAN Access System$361
- OPTICROSS$255
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$223
- EVOQUE$167
- AMPLATZER AMULET$157
- (4067) Tack Endo Sys BTK$146
- CoreValve Evolut$140
- AMPLATZER Occluders$135
- JARDIANCE$125
- SYNERGY$120
- TherOx DS2 Console$113
- Catheter$113
- Downstream Cartridge$113
How this compares
$14,849 in reported general payments places this provider in the 75th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 48 | $48,493 |
| Repatha SureclickEvolocumab | 42 | $30,476 |
| EliquisApixaban | 22 | $26,373 |
| FarxigaDapagliflozin Propanediol | 17 | $12,379 |
| Rosuvastatin Calcium | 91 | $968 |
| Amlodipine Besylate | 89 | $788 |
| Atorvastatin Calcium | 66 | $714 |
| Ezetimibe | 25 | $603 |
| Metoprolol Succinate | 57 | $562 |
| Carvedilol | 42 | $444 |
| Lisinopril | 40 | $384 |
| ClopidogrelClopidogrel Bisulfate | 60 | $364 |
| Losartan Potassium | 32 | $307 |
| Metoprolol Tartrate | 57 | $258 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 24 | $238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $42 | $48,49348 claims |
| PfizerEliquis | $38 | $26,37322 claims |
| AstraZenecaFarxiga | $23 | $12,37917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Virginia Beach
- Deepak TalrejaVirginia Beach$1.5M
- Michael GenVirginia Beach$207K
- Ronald McKechnieVirginia Beach$9K
- Rajiv TayalFredericksburg$984K
- Gansevoort DunningtonRichmond$440K
- Matthew SummersNorfolk$308K
- Noah JonesFalls Church$238K
- Jeremy BockLeesburg$202K
- Wayne BatchelorFalls Church$196K
- Matthew SherwoodFalls Church$193K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.